Full Year 2022 Financial Guidance
Vertex today provided full year 2022 financial guidance. Vertex’s product revenue guidance is primarily based on expectations for continued strong performance of TRIKAFTA in the U.S., and KAFTRIO outside the U.S. Vertex’s product revenue guidance reflects management’s expectations for approved products in countries where Vertex has already secured reimbursement.
Vertex’s guidance is summarized below:
|
|
FY 2022 |
|
|
|
|
|
|
Product revenues |
$8.4 to $8.6 billion |
|
|
|
|
|
|
Combined GAAP R&D and SG&A expenses (2) |
$3.30 to $3.45 billion |
|
|
Combined Non-GAAP R&D and SG&A expenses (2) |
$2.70 to $2.75 billion |
|
|
Non-GAAP effective tax rate |
21% to 22% |
Key Business Highlights